P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In

Breaking News

P&T TV

Will mobile devices and apps have a downside?

Despite the convenience of smartphones, tablets, and the many applications they offer to aid physicians, some health care experts are worried about the concerns mobile devices may raise relating to consistency, accuracy, security, and synchronization with other platforms, says F. Randy Vogenberg, RPh, PhD.

March 2014 interview

P&T Community

Update Your Registration Profile

Haven't received your weekly newsletters about the new features on PTcommunity.com? Check your newsletter status by clicking here. Scroll down to the question, 'Check here if you would like to receive our e-newsletter?' and choose 'Yes' or 'No.'

Having trouble with the site? Send an email.

Free App

MediMedia App IconManaged Care, and P&T are available for free on multiple mobile platforms and devices. For Apple and iOS devices, visit the Apple Store and download the free digital application for Managed Care and P&T.

Users of Android, Blackberry, Nook, and Kindle can view the mobile version on their respective devices by visiting these Web sites: Managed Care and P&T.

P&T Journal
for September 2014

Features

Health Care & Law

Legal Risk Management Opportunities, Pharmacy Practice, and P&T Committees

Hospitals Struggle With ACA Challenges

Drug–Gene Interactions: Inherent Variability in Drug Maintenance Dose Requirements

Schizophrenia: Overview and Treatment Options

Pipeline Plus

Schizophrenia Therapy Options Increasing

Departments

Medication Errors

Too Many Abandon the “Second Victims” of Medical Errors

Prescription: Washington

New Controversy for 340B: OPA Rebuffs Ruling by Court

New Drugs/Drug News/New Medical Devices

Pharmaceutical Approval Update

Drug Forecast

Loxapine Inhalation Powder (Adasuve)

About P&T

Contacts:

Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager

David B. Nash, MD, MBA, editor-in-chief of P&T, is Dean of the Jefferson School of Population Health, Philadelphia. From 1996 to 2003, he served as the first Associate Dean for Health Policy at Jefferson Medical College. In 2004, he was named Co-director of the Masters Program in Public Health at Jefferson.

View the rest of the Editorial Board here.

Call For Papers

P&T Journal is now accepting article submissions from its readers. We welcome a wide variety of manuscripts, including drug class reviews, disease state management reviews, pharmacoeconomic analyses, outcomes research evaluations, DUEs, P&T committee experiences, commentaries, book reviews, and letters to the editor. Please see our author guidelines below or contact the editor, Sonja Sherritze, via phone 267-685-2779 or email: ssherritze@medimedia.com.

Guidelines For Authors

Subscribe to P&T

Print Edition

Resources

Clinical Briefs

Pharmacy Policies/Procedures: Forms and guidelines

Cost Calculators: Exclusive online tools to evaluate your pharmacy costs

Links: A comprehensive map of web links to the world of managed care pharmacy

Recent Headlines

Formulary Kits

Abilify Maintena™
(aripiprazole) for extended-release injectable suspension

ADASUVE®
(loxapine) inhalation powder

BYDUREON® Pen
(exenatide extended-release for injectable suspension)

DUAVEE™
(Conjugated Estrogens/ Bazedoxifene)

ELIQUIS®
(apixaban) tablets

Please click for FULL PRESCRIBING INFORMATION including Boxed WARNINGS

Farxiga™
(dapagliflozin)

GRANIX™
(tbo-filgrastim) Injection

Injectafer®
(ferric carboxymaltose injection)

INVOKAMET
(canagliflozin and metformin HCI)

INVOKANA®
(canagliflozin)

JAKAFI®
(ruxolitinib)

Plegridy™
(peginterferon beta-1a)

Quillivant XR™
(methylphenidate HCl) for extended-release oral suspension, CII

Please click for FULL PRESCRIBING INFORMATION, including Boxed WARNING

Simponi®
(golimumab)

SIMPONI® ARIA™
(golimumab) for infusion